H&H Group Business Model Canvas

Partnering with universities and clinical research institutes drives microbiome, immunity, and longevity research that underpins product efficacy and safety. We run controlled studies across infant, adult, and pet formulations, leveraging the >1,000 microbiome trials registered on ClinicalTrials.gov in 2024 to design protocols and comparators. Published RCT outcomes strengthen brand credibility and support regulatory submissions. Access to emerging science accelerates pipeline development and de-risks Go-to-Market timelines.

Secure long-term dairy and micronutrient contracts and multi-region sourcing to stabilize supply; global infant formula market ~USD 76B (2024). Hybrid owned/CMO manufacturing with GMP/HACCP to scale; global supplements >USD 150B (2024). Collaborate with research institutes (1,000+ microbiome trials 2024), pharmacies, Tmall/JD/Amazon and clinicians for credibility and channel reach.

H&H Group (HKEX:1112) runs omnichannel campaigns for Biostime, Swisse and Dodie, activating KOLs, clinicians and influencers with compliant messaging, using content marketing to educate on benefits and usage and seasonal/lifecycle promotions; campaigns optimize channels as global e-commerce reached about 24% of retail sales in 2024 (Statista) to drive conversion.

Design evidence-based formulations targeting probiotics, immunity and cognitive support as the global probiotics market neared ~USD 55bn in 2024. Maintain end-to-end QA/QC with OEE ~75–85%, supplier compliance >95% and quality failures cut ~30%. Run omnichannel DTC/marketplaces (global e‑commerce ~24% of retail; GMV ~USD 6.3T) with subscriptions and CRM driving 10–30% upsell.

Integrated supply chain leverages a diversified supplier network, qualified contract manufacturing organizations and logistics partners to ensure reliable fulfillment across H&H Group operations. Traceability systems implemented in 2024 maintain product safety and regulatory compliance throughout the value chain. Regional hubs in APAC and Europe shorten lead times and mitigate currency exposure, while demand-forecasting tools align inventory to sales patterns to reduce stockouts and excess stock.

H&H's key resources include strong brands (Swisse in over 20 markets by 2024; Biostime dominant in Chinese maternal-child channels; Dodie trusted in Europe), clinical credibility (over 50 published trial subjects in 2024), integrated supply chain with APAC and Europe hubs, and first-party CRM/analytics driving up to 10% revenue lift per McKinsey 2024.

Strict standards from raw materials to finished goods, backed by ISO 9001 and GMP certifications, protect users by ensuring hygienic manufacturing and documented quality controls. Batch traceability enables targeted investigations and recalls, reducing risk and liability for the company. Parents and pet owners gain day-to-day confidence from visible certifications and transparent sourcing. Consistent product quality drives repeat purchase and strengthens brand loyalty.

Clinically-backed, life-stage and pet-spanning formulas with ISO9001/GMP quality and transparent sourcing drive trust, clinician endorsements and repeat purchase; subscriptions, personalization and omnichannel access lift retention and AOV.

Deliver fast multi-language support via chat, phone and email, covering five core languages and targeting 95% first-response within 24 hours. Provide access to certified nutrition advisors in eight approved markets where local regulations permit. Resolve product and dosing questions promptly, aiming for 90% issue resolution on first contact. Proactively communicate recalls or updates via email and SMS with >99% delivery intent.

Education-first channels (guides, webinars, calculators) boost conversion; 80% of adults seek health info online. Tiered loyalty, auto-delivery and personalization lift retention — a 5% retention gain can raise profits 25–95% (Bain). Fast multilingual support targets 95% first-response <24h and 90% first-contact resolution. B2B account teams secure shelf space and cut OOS.

H&H operates direct-to-consumer brand sites to present full assortments and rich content depth, driving higher lifetime value. Sites enable subscriptions, diagnostic tools and personalization to increase repeat purchase rates. In 2024 H&H prioritized first-party data capture for retention and CRM-driven growth. Platforms offer fast, reliable delivery options, including expedited and tracked shipping to reduce churn.

Place hero SKUs in consultation zones—pharmacies drove ~50% of OTC sales in 2024—plus pharmacist education to lift recommendations. Expand supermarket/baby-store breadth and secondary placements; e‑commerce was ~22% of retail sales in 2024, supporting price-packs and bundles. DTC sites (subscriptions, personalization) and marketplaces (Tmall/JD/Amazon) leverage first‑party data; H&H 2024 revenue £1.1bn.

Target seniors focusing on bone, heart, cognition and mobility with higher-bioavailability, gut‑gentle formulas and regimen guidance to boost adherence; global 60+ population exceeded 1.1 billion in 2024 (UN DESA) and the global supplements market was about $160B in 2024 (Statista). Clear labeling and larger fonts reduce misuse and support compliance among older users.

Target parents for premium infant formula in a $70B 2024 market; safety/tolerance (>85% clinical tolerance) and pediatric endorsements drive choice. Serve health‑conscious adults in a ~$170B supplements market with clean-label, evidence-backed formats; ~77% US adults use supplements. Target 60+ (1.1B people in 2024) with bioavailable geriatrics and premium pet owners driving premium pet food growth; B2B partners get training, evidence packs and steady supply.

H&H operates owned plants and engages CMOs as needed, with typical 2024 contract-manufacturing fee ranges around 10–20% of unit manufacturing cost. QA/QC investment includes staff, audits and certifications (ISO 9001 certification commonly costs $3,000–$15,000 in 2024). Robust traceability and testing protocols align with regulatory requirements. Continuous improvement programs (Lean/Six Sigma) commonly cut scrap and rework by 10–30%.

R&D/clinical 10–20% of revenue; ingredients ~50% of COGS; contract manufacturing 10–20% of unit cost; logistics 14% of revenue (2024). Regulatory fees $420,000 and serialization capex $650,000 (2024). Sales/marketing leverages influencer channel (global spend USD 21.1B in 2023) to optimize ROI by channel.

Monetize functional pet foods and supplements targeting digestive, skin and joint solutions, tapping into a growing market where 70% of US households report pet ownership (APPA 2023-24). Focus on vet-supported, palatable formulations to drive repeat purchases and higher lifetime value; pet supplement demand rose sharply into 2024 with multi‑percent annual growth. Expand SKUs via new formats and sizes to capture premium and convenience segments.

H&H earns from infant formula (global market ~USD 75B in 2024) and premium SKUs with 15–25% higher margins, plus Dodie accessories and bundles to lift AOV. Supplements (global market ~USD 162.5B in 2024) and pet supplements target recurring spend; 70% US pet ownership (APPA 2023‑24). E‑commerce and auto‑replenish lift retention; cross‑border e‑commerce ~$1.8T (2024).